Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 8/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30681326 | 0.88 | NOTUM (0.40) | NOTUMAKT1SCN9ACACNA1SEPHX2 | |
| SCHEMBL30681262 | 0.88 | SCN9A (0.42) | NOTUMSCN9ABCHEDRD1UCHL1 | |
| SCHEMBL30681310 | 0.88 | SCN9A (0.42) | NOTUMSCN9ABCHEDRD1UCHL1 | |
| SCHEMBL30681464 | 0.81 | NOTUM (0.41) | NOTUMBCHEDRD1UCHL1 | |
| SCHEMBL30681223 | 0.81 | NOTUM (0.41) | NOTUMBCHEDRD1UCHL1 | |
| SCHEMBL30390423 | 0.77 | DRD2 (0.47) | NOTUMBCHE | |
| SCHEMBL1760601 | 0.77 | DRD2 (0.47) | NOTUMBCHE | |
| SCHEMBL29571640 | 0.77 | DRD2 (0.47) | NOTUMBCHE | |
| SCHEMBL3061256 | 0.77 | DRD2 (0.47) | NOTUMBCHE | |
| SCHEMBL30681381 | 0.77 | DRD2 (0.47) | NOTUMBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | NOTUM 2701/4885AKT1 3830/4885SCN9A 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.